ERAP1

Last updated

Endoplasmic reticulum aminopeptidase 1 (ERAP1) is an M1 zinc aminopeptidase [Uniprot, A0A0A7E6D4] involved in the antigen processing and presentation pathway. ERAP1 is mainly located in the endoplasmic reticulum (ER), where it trims peptides at their N-terminus, adapting them for presentation by MHC class I molecules (MHC-I) [1] .

Contents

ERAP1
3QNF.pdb.png
Available structures
PDB Ortholog search: PDBe RCSB
Identifiers
Aliases ERAP1 , A-LAP, ALAP, APPILS, ARTS-1, ARTS1, ERAAP, ERAAP1, PILS-AP, PILSAP, endoplasmic reticulum aminopeptidase 1
External IDs OMIM: 606832 MGI: 1933403 HomoloGene: 140581 GeneCards: ERAP1
Orthologs
SpeciesHumanMouse
Entrez

51752

80898

Ensembl

ENSG00000164307

ENSMUSG00000021583

UniProt

Q9NZ08

Q9EQH2

RefSeq (mRNA)

NM_001040458
NM_001198541
NM_016442
NM_001349244

NM_030711

RefSeq (protein)

NP_001035548
NP_001185470
NP_057526
NP_001336173

NP_109636

Location (UCSC) Chr 5: 96.76 – 96.81 Mb Chr 13: 74.79 – 74.84 Mb
PubMed search [4] [5]
Wikidata
View/Edit Human View/Edit Mouse

Nomenclature

Historical names of ERAP1, [HUGO Gene Nomenclature Committee]:

Function

Antigen processing and presentation

Efficient presentation of antigenic peptides by MHC class I molecules provides the key signal for adaptive immune responses by cytotoxic (CD8+) T lymphocytes. In the "endogenous" antigen presentation pathway, proteins synthesized by cells undergo cytosolic degradation and some of their peptide fragments are transported to the ER, where suitable-length peptides are loaded onto MHC class I molecules. In the ER, ERAP1 shortens longer peptides to the optimal length for stable binding onto MHC class I molecules. ERAP1, like other APP components, is induced by interferon-γ, a cytokine inducing antigen presentation [6] . ERAP1 preferentially trims N-extended substrates of 9-16 residues to optimally sized 8-10 residue peptides [7] . This “molecular ruler” mechanism is unique to ERAP1. ERAP1 also functions in the presentation of extracellular antigens in the cross-presentation pathway.

ERAP1 "trimming" modulates the peptide repertoire presented by MHC class I molecules   and thereby shapes the adaptive immune response [6] [8] [9] . In murine models, ERAAP (the murine homologue of human ERAP1) deficiency results in a strong alteration and increased immunogenicity of the peptide repertoire presented by MHC-I [10] . Murine models with genetic deficiency for ERAAP have been instrumental for understanding the role of peptide trimming in the ER [8] [11] [12] .

Other functions

Besides peptide trimming in the ER, ERAP1 has been proposed to perform additional functions depending on its location.

ERAP1 can be secreted into the extracellular space in response to inflammatory stimuli, which can lead to the activation of immune cells, such as macrophages or natural killer cells, and enhanced expression of pro-inflammatory cytokines [13] .

Genetics

Gene

The ERAP1 gene (HGNC: 18173) is located at the long arm of chromosome 5 (5q15). The gene is ~47Kb in length [14] and contains 20 exons and 19 introns [15] , which encode 9 different splice variants. The coding sequence shows a high degree of conservation among placental mammals (>80% identity). The sequences of 227 ERAP1 orthologs identified in approximately 200 species are available [16] .

SNPs

ERAP1 is a polymorphic gene that has many single nucleotide variants (SNVs) including several common missense variants that alter the ERAP1 amino acid sequence. The various combinations of common SNVs in ERAP1 organize into distinct haplotypes that encode different protein isoforms often referred to as “allotypes” [17] . The allotypes of ERAP1 can broadly be categorized based on their enzymatic activity ranging from “high” to “low” [18] [19] . The enzymatic activity of ERAP1 is dependent on substrate recognition of the peptide, seen by the trimming efficiency of specific peptide substrates varying significantly for a given allotype. As is the case for allotype 10, a poor trimming allotype, shown to be tenfold less active compared to the ancestral allotype in hydrolysis of the substrate l-leucine-7-amido-4-methylcoumarin (Leu-AMC) [19] .

Clinical significance

Genetic variants and haplotypes (i.e., allotypes) of ERAP1 have been associated with a wide variety of inflammatory conditions, infectious diseases, and cancer.

In particular, ERAP1 is a major risk gene identified in genome-wide association studies of MHC-I associated inflammatory conditions (or “MHC-I-opathies”), including Ankylosing Spondylitis [20] , Bechet’s disease [21] , Birdshot Uveitis [22] , and Psoriasis [23] . In these conditions, ERAP1 is often in epistasis with the primary risk MHC-I allele [24] . Other disease associations include Insulin dependent Diabetes Mellitus and Multiple Sclerosis [25] . Historically, ERAP1 gene associations were first reported in Hypertension [26] . Emerging evidence links ERAP1 SNVs to cancer development, and susceptibility to Infectious disease [27] , such as ERAP1 SNVs that modify the resistance to influenza virus infection [28] .

Protein

Structure

ERAP1 belongs to the oxytocinase subfamily of the M1-family of zinc metalloproteases. It is composed of four structural domains. Domain I (residues 1-254) consists of an eight-stranded ß-sheet and provides binding sites for the N-terminus of substrates. It fits against the catalytic domain II and engages with domain IV through an elongated loop. Domain II (residues 255-529) is the thermolysin-like catalytic domain, composed by an alpha-helix and a five stranded beta sheet. This sheet comprises the specific for exopeptidases GAMEN motif which creates one part of the substrate binding-cleft. The catalytic Zn atom is coordinated by the residues His353, His357 and Glu386, found in the zinc-binding motif (H-E-X-X-H-X18-E) on the helix 6a. Domain III (residues 530-614) is composed by two beta-sheets forming a beta sandwich and acts as a linker between domains II and IV. Finally, domain IV (615-941) consists mainly of a-helices and exhibits a bowl-shaped form. At the closed (active) state, it juxtaposes with domain II forming a large internal cavity, which holds the C-term substrate binding site. It is the most variable domain among this family of aminopeptidases [29] [30] .

Mechanism

ERAP1 uses a catalytic mechanism similar to the one proposed for LTA4 hydrolase [29] . ERAP1 adopts a thermolysin­like fold and has been crystallized in two distinct conformations: a. the open and b. the closed. In the open conformation, domain IV lies away from the active site thus making the internal cavity more accessible to substrates. In the closed conformation, the internal cavity is occluded from the external solvent, and it is of adequate size to accommodate a 16-residue peptide. The catalytic residues and in particular Tyr438 are optimally positioned for catalysis in the closed conformation. Consequently, substrate binding is hypothesized to take place in the open conformation, while N-terminal bond cleavage takes place in the closed one [29] [30] . It has been proposed that binding of substrate or small inhibitors induces conformational closing of ERAP1 in solution [31] .

ERAP1 prefers peptide substrates 9-16 amino acids long and is much less active for peptides 8-9 amino acids long. It is considered that ERAP1 uses a “molecular ruler” mechanism, according to which the substrate binds through its hydrophobic C-terminus in a hydrophobic pocket at the junction of domain III and domain IV and the N-terminus binds to the active site. When the length of the peptide is shorter than 8 or 9 amino acids, the peptide is too short to reach the active site, limiting rates of cleavage [7] .

ERAP1 has a wide substrate specificity with a preference for hydrophobic residues (e.g. leucine and methionine) at the N-terminus of the peptide substrate [32] [33] . Tryptophan, arginine, cysteine and charged amino acids, like aspartic and glutamic acid, are poorly removed [30] [32] . ERAP1’s trimming efficiency can also be influenced by the internal sequence of the peptide, with preferences for hydrophobic and positively charged residues [32] .

Interactions

ERp44

Hisatsune et al. demonstrated, by co-immunoprecipitation, an interaction between ERAP1 and the disulfide-shuffling chaperone ERp44, facilitated by disulfide bonds formed with cysteine residues in the exon 10 loop of ERAP1 [34] . This interaction was proposed to be the main mechanism for ER retention.

Heterodimerization with ERAP2

Some experimental evidence has indicated the possibility of heterodimer formation between ERAP1 and ERAP2, another member of the oxytocinase sub-family of M1 aminopeptidases, that shares structural and functional similarities. The co-elution of ERAP1 and ERAP2 was detected through microsome fractionation, in the 230 kDa fraction, suggesting the formation of heterodimers [35] . Proximity ligation assay analysis suggested a direct physical interaction between the two enzymes [35] . A leucine zipper mediated ERAP1/ERAP2 complex exhibited enhanced trimming efficiency compared to a mixture of the two enzymes [36] . Computational dynamics showed that ERAP1/ERAP2 heterodimerization could be mediated by the exon 10 loop [37] , known to be involved in ERAP1-ERp44 interactions [34] .

MHC I proposed interaction

Chen et al. suggested that ERAP1 can trim N-terminally extended precursor antigenic peptides when bound onto MHC I [38] . However, a re-evaluation of this trimming model by kinetic and biochemical analyses suggested that most MHC-I bound peptides had limited to no access to the active site of ERAP1 [39] .

Therapeutic approaches and pharmacology

Therapeutic approaches for ERAP1 regulation rely mostly on the development of small molecule inhibitors. The most explored classes of inhibitors for ERAP1 are the catalytic or the allosteric site ones.

ERAP1 catalytic site inhibitors

Phosphinic derivatives

The first generation of  ERAP1 inhibitors is a series of phosphinic pseudopeptides derived from a rational design approach targeting the catalytic zinc-binding site, in 2013 [1] . Notably, DG013A (Table 1) displayed high potency (ERAP1 IC50 = 33 nM) but poor selectivity against ERAP2 and IRAP, with reported SAR optimization studies demonstrating the importance of side chains at positions P1’ and P2’ [40] [41] . A high-resolution crystal structure of phosphinic analogue DG046 bound in the active site of ERAP1, has been obtained [42] .

DABA analogues

A novel family of zinc-targeting diaminobenzoic acid (DABA) compounds were rationally designed and developed in 2013, displaying micromolar potency for ERAP1 inhibition (compound 2, IC50 = 2 μM, Table 1). Moderate selectivity over ERAP2 and IRAP with additional optimization efforts based on extensive investigation of SAR has been achieved [43] [44] .

Urea derivatives

In 2020, urea derivative 3 (Table 1) was identified via high-throughput screening (HTS), as a competitive inhibitor of ERAP1 aminopeptidase activity (IC50 = 6.9 μM) with increased selectivity over ERAP2 and IRAP [45] . SAR exploration and docking studies showed that the N-acetylpiperazine carbonyl group was critical for the activity via its zinc-binding group properties [45] .

ERAP1 allosteric site inhibitors

Benzofurans

This family of compounds were identified as potential allosteric (C-terminus recognition site of peptides) inhibitor via fluorescence-based high-throughput screening in 2021 [46] . Compound 4 (Table 1) displayed high potency (ERAP1 IC50 = 34 nM) and at the same time selectivity against ERAP2 and IRAP [46] .

Sulfonamides

Sulfonamide compound 5 (Table 1) was identified through high-throughput screening studies as a potential allosteric selective inhibitor, binding at the interface between domain II and IV of ERAP1. It activates small peptide hydrolysis but effectively inhibits processing of long peptides with 8−13 residues (IC50 = 5.3 μM) and displays selectivity over ERAP2 and IRAP [45] .

ERAP1 clinical trials

As of 2023, an ERAP1 Inhibitor (GRWD5769) developed by Grey Wolf Therapeutics has entered phase I/II. Its safety, tolerability, efficacy, and pharmacokinetics are being evaluated in patients with viral associated solid tumours (head and neck squamous cell carcinoma, cervical cancer, and hepatocellular carcinoma) that are particularly sensitive to ERAP1 inhibition, as monotherapy, or in combination with PD-1 immune checkpoint Inhibitor Libtayo® (cemiplimab) [47] .

Related Research Articles

<span class="mw-page-title-main">Calreticulin</span> Soluble protein

Calreticulin also known as calregulin, CRP55, CaBP3, calsequestrin-like protein, and endoplasmic reticulum resident protein 60 (ERp60) is a protein that in humans is encoded by the CALR gene.

<span class="mw-page-title-main">Protein disulfide-isomerase</span> Class of enzymes

Protein disulfide isomerase, or PDI, is an enzyme in the endoplasmic reticulum (ER) in eukaryotes and the periplasm of bacteria that catalyzes the formation and breakage of disulfide bonds between cysteine residues within proteins as they fold. This allows proteins to quickly find the correct arrangement of disulfide bonds in their fully folded state, and therefore the enzyme acts to catalyze protein folding.

<span class="mw-page-title-main">MHC class I</span> Protein of the immune system

MHC class I molecules are one of two primary classes of major histocompatibility complex (MHC) molecules and are found on the cell surface of all nucleated cells in the bodies of vertebrates. They also occur on platelets, but not on red blood cells. Their function is to display peptide fragments of proteins from within the cell to cytotoxic T cells; this will trigger an immediate response from the immune system against a particular non-self antigen displayed with the help of an MHC class I protein. Because MHC class I molecules present peptides derived from cytosolic proteins, the pathway of MHC class I presentation is often called cytosolic or endogenous pathway.

<span class="mw-page-title-main">T-cell receptor</span> Protein complex on the surface of T cells that recognizes antigens

The T-cell receptor (TCR) is a protein complex found on the surface of T cells, or T lymphocytes, that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules. The binding between TCR and antigen peptides is of relatively low affinity and is degenerate: that is, many TCRs recognize the same antigen peptide and many antigen peptides are recognized by the same TCR.

Cross-presentation is the ability of certain professional antigen-presenting cells (mostly dendritic cells) to take up, process and present extracellular antigens with MHC class I molecules to CD8 T cells (cytotoxic T cells). Cross-priming, the result of this process, describes the stimulation of naive cytotoxic CD8+ T cells into activated cytotoxic CD8+ T cells. This process is necessary for immunity against most tumors and against viruses that infect dendritic cells and sabotage their presentation of virus antigens. Cross presentation is also required for the induction of cytotoxic immunity by vaccination with protein antigens, for example, tumour vaccination.

<span class="mw-page-title-main">Calnexin</span> Mammalian protein found in Homo sapiens

Calnexin (CNX) is a 67kDa integral protein of the endoplasmic reticulum (ER). It consists of a large N-terminal calcium-binding lumenal domain, a single transmembrane helix and a short, acidic cytoplasmic tail. In humans, calnexin is encoded by the gene CANX.

<span class="mw-page-title-main">Aminopeptidase</span> Class of enzymes

Aminopeptidases are enzymes that catalyze the cleavage of amino acids from the N-terminus (beginning), of proteins or peptides. They are found in many organisms; in the cell, they are found in many organelles, in the cytosol, and as membrane proteins. Aminopeptidases are used in essential cellular functions, and are often zinc metalloenzymes, containing a zinc cofactor.

<span class="mw-page-title-main">Leucyl/cystinyl aminopeptidase</span> Protein-coding gene in the species Homo sapiens

Leucyl/cystinyl aminopeptidase, also known as cystinyl aminopeptidase (CAP), insulin-regulated aminopeptidase (IRAP), human placental leucine aminopeptidase (PLAP), oxytocinase, and vasopressinase, is an enzyme of the aminopeptidase group that in humans is encoded by the LNPEP gene.

<span class="mw-page-title-main">Antigen presentation</span> Vital immune process that is essential for T cell immune response triggering

Antigen presentation is a vital immune process that is essential for T cell immune response triggering. Because T cells recognize only fragmented antigens displayed on cell surfaces, antigen processing must occur before the antigen fragment can be recognized by a T-cell receptor. Specifically, the fragment, bound to the major histocompatibility complex (MHC), is transported to the surface of the cell Antigen-Presenting Cell, a process known as presentation. If there has been an infection with viruses or bacteria, the cell Antigen-Presenting Cell will present an endogenous or exogenous peptide fragment derived from the antigen by MHC molecules. There are two types of MHC molecules which differ in the behaviour of the antigens: MHC class I molecules (MHC-I) bind peptides from the cell cytosol, while peptides generated in the endocytic vesicles after internalisation are bound to MHC class II (MHC-II). Cellular membranes separate these two cellular environments - intracellular and extracellular. Each T cell can only recognize tens to hundreds of copies of a unique sequence of a single peptide among thousands of other peptides presented on the same cell, because an MHC molecule in one cell can bind to quite a large range of peptides. Predicting which antigens will be presented to the immune system by a certain MHC/HLA type is difficult, but the technology involved is improving.

<span class="mw-page-title-main">MHC class II</span> Protein of the immune system

MHC Class II molecules are a class of major histocompatibility complex (MHC) molecules normally found only on professional antigen-presenting cells such as dendritic cells, macrophages, some endothelial cells, thymic epithelial cells, and B cells. These cells are important in initiating immune responses.

<span class="mw-page-title-main">HLA-E</span> Protein-coding gene in the species Homo sapiens

HLA class I histocompatibility antigen, alpha chain E (HLA-E) also known as MHC class I antigen E is a protein that in humans is encoded by the HLA-E gene. The human HLA-E is a non-classical MHC class I molecule that is characterized by a limited polymorphism and a lower cell surface expression than its classical paralogues. The functional homolog in mice is called Qa-1b, officially known as H2-T23.

The unfolded protein response (UPR) is a cellular stress response related to the endoplasmic reticulum (ER) stress. It has been found to be conserved between mammalian species, as well as yeast and worm organisms.

<span class="mw-page-title-main">Tapasin</span> Type of protein

TAP-associated glycoprotein, also known as tapasin or TAPBP, is a protein that in humans is encoded by the TAPBP gene.

<span class="mw-page-title-main">PDIA3</span> Protein-coding gene in the species Homo sapiens

Protein disulfide-isomerase A3 (PDIA3), also known as glucose-regulated protein, 58-kD (GRP58), is an isomerase enzyme encoded by the autosomal gene PDIA3 in humans. This protein localizes to the endoplasmic reticulum (ER) and interacts with lectin chaperones calreticulin and calnexin (CNX) to modulate folding of newly synthesized glycoproteins. It is thought that complexes of lectins and this protein mediate protein folding by promoting formation of disulfide bonds in their glycoprotein substrates.

<span class="mw-page-title-main">HLA-F</span> Protein-coding gene in the species Homo sapiens

HLA class I histocompatibility antigen, alpha chain F is a protein that in humans is encoded by the HLA-F gene. It is an empty intracellular molecule that encodes a non-classical heavy chain anchored to the membrane and forming a heterodimer with a β-2 microglobulin light chain. It belongs to the HLA class I heavy chain paralogues that separate from most of the HLA heavy chains. HLA-F is localized in the endoplasmic reticulum and Golgi apparatus, and is also unique in the sense that it exhibits few polymorphisms in the human population relative to the other HLA genes; however, there have been found different isoforms from numerous transcript variants found for the HLA-F gene. Its pathways include IFN-gamma signaling and CDK-mediated phosphorylation and removal of the Saccharomycescerevisiae Cdc6 protein, which is crucial for functional DNA replication.

<span class="mw-page-title-main">NGLY1</span> Protein-coding gene in the species Homo sapiens

PNGase also known as N-glycanase 1 or peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase is an enzyme that in humans is encoded by the NGLY1 gene. PNGase is a de-N-glycosylating enzyme that removes N-linked or asparagine-linked glycans (N-glycans) from glycoproteins. More specifically, NGLY1 catalyzes the hydrolysis of the amide bond between the innermost N-acetylglucosamine (GlcNAc) and an Asn residue on an N-glycoprotein, generating a de-N-glycosylated protein, in which the N-glycoylated Asn residue is converted to asp, and a 1-amino-GlcNAc-containing free oligosaccharide. Ammonia is then spontaneously released from the 1-amino GlcNAc at physiological pH (<8), giving rise to a free oligosaccharide with an N,N’-diacetylchitobiose structure at the reducing end.

Immunoevasins are proteins expressed by some viruses that enable the virus to evade immune recognition by interfering with MHC I complexes in the infected cell, therefore blocking the recognition of viral protein fragments by CD8+ cytotoxic T lymphocytes. Less frequently, MHC II antigen presentation and induced-self molecules may also be targeted. Some viral immunoevasins block peptide entry into the endoplasmic reticulum (ER) by targeting the TAP transporters. Immunoevasins are particularly abundant in viruses that are capable of establishing long-term infections of the host, such as herpesviruses.

<span class="mw-page-title-main">ERAP2</span> Protein-coding gene in the species Homo sapiens

Endoplasmic reticulum aminopeptidase 2 is an aminopeptidase in humans involved in antigen presentation. It is encoded by the ERAP2 gene.

<span class="mw-page-title-main">Peptide loading complex</span>

The peptide-loading complex (PLC) is a short-lived, multisubunit membrane protein complex that is located in the endoplasmic reticulum (ER). It orchestrates peptide translocation and selection by major histocompatibility complex class I (MHC-I) molecules. Stable peptide-MHC I complexes are released to the cell surface to promote T-cell response against malignant or infected cells. In turn, T-cells recognize the activated peptides, which could be immunogenic or non-immunogenic.

<span class="mw-page-title-main">Margarita del Val</span> Spanish chemist

Margarita del Val Latorre is a Spanish chemist, immunologist, and virologist. She coordinates the Salud Global platform run by the Spanish National Research Council (CSIC).

References

  1. 1 2 Shastri N, Nagarajan N, Lind KC, Kanaseki T (February 2014). "Monitoring peptide processing for MHC class I molecules in the endoplasmic reticulum". Current Opinion in Immunology. 26: 123–127. doi:10.1016/j.coi.2013.11.006. ISSN   0952-7915. PMC   3932006 . PMID   24556408.
  2. 1 2 3 GRCh38: Ensembl release 89: ENSG00000164307 – Ensembl, May 2017
  3. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000021583 – Ensembl, May 2017
  4. ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  6. 1 2 Saric T, Chang SC, Hattori A, York IA, Markant S, Rock KL, Tsujimoto M, Goldberg AL (December 2002). "An IFN-γ–induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I–presented peptides". Nature Immunology. 3 (12): 1169–1176. doi:10.1038/ni859. ISSN   1529-2916. PMID   12436109.
  7. 1 2 Chang SC, Momburg F, Bhutani N, Goldberg AL (2005-11-22). "The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a "molecular ruler" mechanism". Proceedings of the National Academy of Sciences. 102 (47): 17107–17112. Bibcode:2005PNAS..10217107C. doi: 10.1073/pnas.0500721102 . ISSN   0027-8424. PMC   1287962 . PMID   16286653.
  8. 1 2 Hammer GE, Gonzalez F, Champsaur M, Cado D, Shastri N (January 2006). "The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules". Nature Immunology. 7 (1): 103–112. doi:10.1038/ni1286. ISSN   1529-2916. PMID   16299505.
  9. ↑ Serwold T, Gonzalez F, Kim J, Jacob R, Shastri N (October 2002). "ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum". Nature. 419 (6906): 480–483. Bibcode:2002Natur.419..480S. doi:10.1038/nature01074. ISSN   1476-4687. PMID   12368856.
  10. ↑ Hammer GE, Gonzalez F, James E, Nolla H, Shastri N (January 2007). "In the absence of aminopeptidase ERAAP, MHC class I molecules present many unstable and highly immunogenic peptides". Nature Immunology. 8 (1): 101–108. doi:10.1038/ni1409. ISSN   1529-2916. PMID   17128277.
  11. ↑ Firat E, Saveanu L, Aichele P, Staeheli P, Huai J, Gaedicke S, Nil A, Besin G, Kanzler B, van Endert P, Niedermann G (2007-02-15). "The Role of Endoplasmic Reticulum-Associated Aminopeptidase 1 in Immunity to Infection and in Cross-Presentation". The Journal of Immunology. 178 (4): 2241–2248. doi:10.4049/jimmunol.178.4.2241. ISSN   0022-1767. PMID   17277129.
  12. ↑ York IA, Brehm MA, Zendzian S, Towne CF, Rock KL (2006-06-13). "Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance". Proceedings of the National Academy of Sciences. 103 (24): 9202–9207. Bibcode:2006PNAS..103.9202Y. doi: 10.1073/pnas.0603095103 . ISSN   0027-8424. PMC   1482590 . PMID   16754858.
  13. ↑ Tsujimoto M, Aoki K, Ohnishi A, Goto Y (2020). "Endoplasmic Reticulum Aminopeptidase 1 beyond Antigenic Peptide-Processing Enzyme in the Endoplasmic Reticulum". Biological and Pharmaceutical Bulletin. 43 (2): 207–214. doi:10.1248/bpb.b19-00857. PMID   32009107.
  14. ↑ "ERAP1 endoplasmic reticulum aminopeptidase 1 [Homo sapiens (human)] - Gene - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2024-05-07.
  15. ↑ Hattori A, Matsumoto K, Mizutani S, Tsujimoto M (2001-08-01). "Genomic Organization of the Human Adipocyte-Derived Leucine Aminopeptidase Gene and Its Relationship to the Placental Leucine Aminopeptidase/Oxytocinase Gene". Journal of Biochemistry. 130 (2): 235–241. doi:10.1093/oxfordjournals.jbchem.a002977. ISSN   0021-924X. PMID   11481040.
  16. ↑ "Homo_sapiens - Ensembl genome browser 111". useast.ensembl.org. Retrieved 2024-05-07.
  17. ↑ Tran TM, Colbert RA (July 2015). "Endoplasmic reticulum aminopeptidase 1 and rheumatic disease: functional variation". Current Opinion in Rheumatology. 27 (4): 357–363. doi:10.1097/BOR.0000000000000188. ISSN   1040-8711. PMC   4495904 . PMID   26002027.
  18. ↑ Reeves E, James E (2018-08-31). "The role of polymorphic ERAP1 in autoinflammatory disease". Bioscience Reports. 38 (4). doi:10.1042/BSR20171503. ISSN   0144-8463. PMC   6131210 . PMID   30054427.
  19. 1 2 Hutchinson JP, Temponeras I, Kuiper J, Cortes A, Korczynska J, Kitchen S, Stratikos E (January 2021). "Common allotypes of ER aminopeptidase 1 have substrate-dependent and highly variable enzymatic properties". Journal of Biological Chemistry. 296: 100443. doi: 10.1016/j.jbc.2021.100443 . PMC   8024916 . PMID   33617882.
  20. ↑ Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, Oppermann U, Dilthey A, Pirinen M, Stone MA, Appleton L, Moutsianas L, Leslie S, Wordsworth T, Kenna TJ (August 2011). "Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility". Nature Genetics. 43 (8): 761–767. doi:10.1038/ng.873. ISSN   1546-1718. PMC   3640413 . PMID   21743469.
  21. ↑ Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, Ozyazgan Y, Sacli FS, Erer B, Inoko H, Emrence Z, Cakar A, Abaci N, Ustek D, Satorius C (February 2013). "Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1". Nature Genetics. 45 (2): 202–207. doi:10.1038/ng.2520. ISSN   1061-4036. PMC   3810947 . PMID   23291587.
  22. ↑ Kuiper JJ, Setten Jv, Devall M, Cretu-Stancu M, Hiddingh S, Ophoff RA, Missotten TO, Velthoven Mv, Den Hollander AI, Hoyng CB, James E, Reeves E, Cordero-Coma M, Fonollosa A, Adán A (2018-09-28). "Functionally distinct ERAP1 and ERAP2 are a hallmark of HLA-A29-(Birdshot) Uveitis". Human Molecular Genetics. 27 (24): 4333–4343. doi:10.1093/hmg/ddy319. ISSN   0964-6906. PMC   6276832 . PMID   30215709.
  23. ↑ Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2 (November 2010). "A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1". Nature Genetics. 42 (11): 985–990. doi:10.1038/ng.694. ISSN   1061-4036. PMC   3749730 . PMID   20953190.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  24. ↑ López de Castro JA, Alvarez-Navarro C, Brito A, Guasp P, Martín-Esteban A, Sanz-Bravo A (September 2016). "Molecular and pathogenic effects of endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 in MHC-I-associated inflammatory disorders: Towards a unifying view". Molecular Immunology. 77: 193–204. doi:10.1016/j.molimm.2016.08.005. PMID   27522479.
  25. ↑ Pepelyayeva Y, Amalfitano A (May 2019). "The role of ERAP1 in autoinflammation and autoimmunity". Human Immunology. 80 (5): 302–309. doi:10.1016/j.humimm.2019.02.013. PMID   30817945.
  26. ↑ Yamamoto N, Nakayama J, Yamakawa-Kobayashi K, Hamaguchi H, Miyazaki R, Arinami T (March 2002). "Identification of 33 polymorphisms in the adipocyte-derived leucine aminopeptidase (ALAP) gene and possible association with hypertension". Human Mutation. 19 (3): 251–257. doi:10.1002/humu.10047. ISSN   1059-7794. PMID   11857741.
  27. ↑ Cifaldi L, Romania P, Lorenzi S, Locatelli F, Fruci D (2012-07-04). "Role of Endoplasmic Reticulum Aminopeptidases in Health and Disease: from Infection to Cancer". International Journal of Molecular Sciences. 13 (7): 8338–8352. doi: 10.3390/ijms13078338 . ISSN   1422-0067. PMC   3430237 . PMID   22942706.
  28. ↑ Schott BH, Wang L, Zhu X, Harding AT, Ko ER, Bourgeois JS, Washington EJ, Burke TW, Anderson J, Bergstrom E, Gardener Z, Paterson S, Brennan RG, Chiu C, McClain MT (November 2022). "Single-cell genome-wide association reveals that a nonsynonymous variant in ERAP1 confers increased susceptibility to influenza virus". Cell Genomics. 2 (11): 100207. doi:10.1016/j.xgen.2022.100207. PMC   9718543 . PMID   36465279.
  29. 1 2 3 Kochan G, Krojer T, Harvey D, Fischer R, Chen L, Vollmar M, von Delft F, Kavanagh KL, Brown MA, Bowness P, Wordsworth P, Kessler BM, Oppermann U (2011-05-10). "Crystal structures of the endoplasmic reticulum aminopeptidase-1 (ERAP1) reveal the molecular basis for N-terminal peptide trimming". Proceedings of the National Academy of Sciences. 108 (19): 7745–7750. Bibcode:2011PNAS..108.7745K. doi: 10.1073/pnas.1101262108 . ISSN   0027-8424. PMC   3093473 . PMID   21508329.
  30. 1 2 3 Nguyen TT, Chang SC, Evnouchidou I, York IA, Zikos C, Rock KL, Goldberg AL, Stratikos E, Stern LJ (May 2011). "Structural basis for antigenic peptide precursor processing by the endoplasmic reticulum aminopeptidase ERAP1". Nature Structural & Molecular Biology. 18 (5): 604–613. doi:10.1038/nsmb.2021. ISSN   1545-9993. PMC   3087843 . PMID   21478864.
  31. ↑ Maben Z, Arya R, Georgiadis D, Stratikos E, Stern LJ (2021-09-06). "Conformational dynamics linked to domain closure and substrate binding explain the ERAP1 allosteric regulation mechanism". Nature Communications. 12 (1): 5302. Bibcode:2021NatCo..12.5302M. doi:10.1038/s41467-021-25564-w. ISSN   2041-1723. PMC   8421391 . PMID   34489420.
  32. 1 2 3 Hearn A, York IA, Rock KL (2009-11-01). "The Specificity of Trimming of MHC Class I-Presented Peptides in the Endoplasmic Reticulum". The Journal of Immunology. 183 (9): 5526–5536. doi:10.4049/jimmunol.0803663. ISSN   0022-1767. PMC   2855122 . PMID   19828632.
  33. ↑ Evnouchidou I, Momburg F, Papakyriakou A, Chroni A, Leondiadis L, Chang SC, Goldberg AL, Stratikos E (2008-11-06). El-Shemy HA (ed.). "The Internal Sequence of the Peptide-Substrate Determines Its N-Terminus Trimming by ERAP1". PLOS ONE. 3 (11): e3658. Bibcode:2008PLoSO...3.3658E. doi: 10.1371/journal.pone.0003658 . ISSN   1932-6203. PMC   2573961 . PMID   18987748.
  34. 1 2 Hisatsune C, Ebisui E, Usui M, Ogawa N, Suzuki A, Mataga N, Takahashi-Iwanaga H, Mikoshiba K (June 2015). "ERp44 Exerts Redox-Dependent Control of Blood Pressure at the ER". Molecular Cell. 58 (6): 1015–1027. doi:10.1016/j.molcel.2015.04.008. PMID   25959394.
  35. 1 2 Saveanu L, Carroll O, Lindo V, Del Val M, Lopez D, Lepelletier Y, Greer F, Schomburg L, Fruci D, Niedermann G, van Endert PM (2005-07-01). "Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum". Nature Immunology. 6 (7): 689–697. doi:10.1038/ni1208. ISSN   1529-2908. PMID   15908954.
  36. ↑ Evnouchidou I, Weimershaus M, Saveanu L, van Endert P (2014-07-15). "ERAP1–ERAP2 Dimerization Increases Peptide-Trimming Efficiency". The Journal of Immunology. 193 (2): 901–908. doi:10.4049/jimmunol.1302855. ISSN   0022-1767. PMID   24928998.
  37. ↑ Papakyriakou A, Mpakali A, Stratikos E (2022-04-20). "Can ERAP1 and ERAP2 Form Functional Heterodimers? A Structural Dynamics Investigation". Frontiers in Immunology. 13. doi: 10.3389/fimmu.2022.863529 . ISSN   1664-3224. PMC   9065437 . PMID   35514997.
  38. ↑ Chen H, Li L, Weimershaus M, Evnouchidou I, van Endert P, Bouvier M (2016-08-12). "ERAP1-ERAP2 dimers trim MHC I-bound precursor peptides; implications for understanding peptide editing". Scientific Reports. 6 (1): 28902. Bibcode:2016NatSR...628902C. doi:10.1038/srep28902. ISSN   2045-2322. PMC   4981824 . PMID   27514473.
  39. ↑ Mavridis G, Arya R, Domnick A, Zoidakis J, Makridakis M, Vlahou A, Mpakali A, Lelis A, Georgiadis D, Tampé R, Papakyriakou A, Stern LJ, Stratikos E (May 2020). "A systematic re-examination of processing of MHCI-bound antigenic peptide precursors by endoplasmic reticulum aminopeptidase 1". Journal of Biological Chemistry. 295 (21): 7193–7210. doi: 10.1074/jbc.RA120.012976 . PMC   7247305 . PMID   32184355.
  40. ↑ Zervoudi E, Saridakis E, Birtley JR, Seregin SS, Reeves E, Kokkala P, Aldhamen YA, Amalfitano A, Mavridis IM, James E, Georgiadis D, Stratikos E (2013-12-03). "Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses". Proceedings of the National Academy of Sciences. 110 (49): 19890–19895. Bibcode:2013PNAS..11019890Z. doi: 10.1073/pnas.1309781110 . ISSN   0027-8424. PMC   3856834 . PMID   24248368.
  41. ↑ Kokkala P, Mpakali A, Mauvais FX, Papakyriakou A, Daskalaki I, Petropoulou I, Kavvalou S, Papathanasopoulou M, Agrotis S, Fonsou TM, van Endert P, Stratikos E, Georgiadis D (2016-10-13). "Optimization and Structure–Activity Relationships of Phosphinic Pseudotripeptide Inhibitors of Aminopeptidases That Generate Antigenic Peptides". Journal of Medicinal Chemistry. 59 (19): 9107–9123. doi:10.1021/acs.jmedchem.6b01031. ISSN   0022-2623.
  42. ↑ Giastas P, Neu M, Rowland P, Stratikos E (2019-05-09). "High-Resolution Crystal Structure of Endoplasmic Reticulum Aminopeptidase 1 with Bound Phosphinic Transition-State Analogue Inhibitor". ACS Medicinal Chemistry Letters. 10 (5): 708–713. doi:10.1021/acsmedchemlett.9b00002. ISSN   1948-5875. PMC   6511960 . PMID   31097987.
  43. ↑ Papakyriakou A, Zervoudi E, Theodorakis EA, Saveanu L, Stratikos E, Vourloumis D (September 2013). "Novel selective inhibitors of aminopeptidases that generate antigenic peptides". Bioorganic & Medicinal Chemistry Letters. 23 (17): 4832–4836. doi:10.1016/j.bmcl.2013.07.024. PMID   23916253.
  44. ↑ Papakyriakou A, Zervoudi E, Tsoukalidou S, Mauvais FX, Sfyroera G, Mastellos DC, van Endert P, Theodorakis EA, Vourloumis D, Stratikos E (2015-02-12). "3,4-Diaminobenzoic Acid Derivatives as Inhibitors of the Oxytocinase Subfamily of M1 Aminopeptidases with Immune-Regulating Properties". Journal of Medicinal Chemistry. 58 (3): 1524–1543. doi:10.1021/jm501867s. ISSN   0022-2623. PMID   25635706.
  45. 1 2 3 Maben Z, Arya R, Rane D, An WF, Metkar S, Hickey M, Bender S, Ali A, Nguyen TT, Evnouchidou I, Schilling R, Stratikos E, Golden J, Stern LJ (2020-01-09). "Discovery of Selective Inhibitors of Endoplasmic Reticulum Aminopeptidase 1". Journal of Medicinal Chemistry. 63 (1): 103–121. doi:10.1021/acs.jmedchem.9b00293. ISSN   0022-2623. PMC   8218592 . PMID   31841350.
  46. 1 2 Deddouche-Grass S, Andouche C, Bärenz F, Halter C, Hohwald A, Lebrun L, Membré N, Morales R, Muzet N, Poirot M, Reynaud M, Roujean V, Weber F, Zimmermann A, Heng R (2021-07-08). "Discovery and Optimization of a Series of Benzofuran Selective ERAP1 Inhibitors: Biochemical and In Silico Studies". ACS Medicinal Chemistry Letters. 12 (7): 1137–1142. doi:10.1021/acsmedchemlett.1c00235. ISSN   1948-5875. PMC   8274102 . PMID   34267884.
  47. ↑ "Grey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid Tumours". 28 March 2023.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.